Cargando…

Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins

The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as we...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Till, Rottstegge, Monika, Ruibal, Paula, Gomez-Medina, Sergio, Nelson, Emily V., Escudero-Pérez, Beatriz, Pillny, Matthias, Ly, My Linh, Koundouno, Fara Raymond, Bore, Joseph Akoi, Magassouba, N’Faly, Dahlke, Christine, Günther, Stephan, Carroll, Miles W., Addo, Marylyn M., Muñoz-Fontela, César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552031/
https://www.ncbi.nlm.nih.gov/pubmed/32825479
http://dx.doi.org/10.3390/v12090915
_version_ 1783593312184172544
author Koch, Till
Rottstegge, Monika
Ruibal, Paula
Gomez-Medina, Sergio
Nelson, Emily V.
Escudero-Pérez, Beatriz
Pillny, Matthias
Ly, My Linh
Koundouno, Fara Raymond
Bore, Joseph Akoi
Magassouba, N’Faly
Dahlke, Christine
Günther, Stephan
Carroll, Miles W.
Addo, Marylyn M.
Muñoz-Fontela, César
author_facet Koch, Till
Rottstegge, Monika
Ruibal, Paula
Gomez-Medina, Sergio
Nelson, Emily V.
Escudero-Pérez, Beatriz
Pillny, Matthias
Ly, My Linh
Koundouno, Fara Raymond
Bore, Joseph Akoi
Magassouba, N’Faly
Dahlke, Christine
Günther, Stephan
Carroll, Miles W.
Addo, Marylyn M.
Muñoz-Fontela, César
author_sort Koch, Till
collection PubMed
description The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.
format Online
Article
Text
id pubmed-7552031
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75520312020-10-14 Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins Koch, Till Rottstegge, Monika Ruibal, Paula Gomez-Medina, Sergio Nelson, Emily V. Escudero-Pérez, Beatriz Pillny, Matthias Ly, My Linh Koundouno, Fara Raymond Bore, Joseph Akoi Magassouba, N’Faly Dahlke, Christine Günther, Stephan Carroll, Miles W. Addo, Marylyn M. Muñoz-Fontela, César Viruses Article The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates. MDPI 2020-08-20 /pmc/articles/PMC7552031/ /pubmed/32825479 http://dx.doi.org/10.3390/v12090915 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Koch, Till
Rottstegge, Monika
Ruibal, Paula
Gomez-Medina, Sergio
Nelson, Emily V.
Escudero-Pérez, Beatriz
Pillny, Matthias
Ly, My Linh
Koundouno, Fara Raymond
Bore, Joseph Akoi
Magassouba, N’Faly
Dahlke, Christine
Günther, Stephan
Carroll, Miles W.
Addo, Marylyn M.
Muñoz-Fontela, César
Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
title Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
title_full Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
title_fullStr Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
title_full_unstemmed Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
title_short Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins
title_sort ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552031/
https://www.ncbi.nlm.nih.gov/pubmed/32825479
http://dx.doi.org/10.3390/v12090915
work_keys_str_mv AT kochtill ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT rottsteggemonika ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT ruibalpaula ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT gomezmedinasergio ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT nelsonemilyv ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT escuderoperezbeatriz ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT pillnymatthias ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT lymylinh ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT koundounofararaymond ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT borejosephakoi ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT magassoubanfaly ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT dahlkechristine ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT guntherstephan ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT carrollmilesw ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT addomarylynm ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins
AT munozfontelacesar ebolavirusdiseasesurvivorsshowmoreefficientantibodyimmunitythanvaccineesdespitesimilarlevelsofcirculatingimmunoglobulins